Immatics Biotechnologies completes blank-check deal with Arya Sciences Acquisition Corp., begins trading
Immatics N.V. (Nasdaq: IMTX) is the latest company with ties to Houston to complete a blank-check deal.
Formerly known as Immatics Biotechnologies GmbH, the Germany-based company has its U.S. office at 2201 W. Holcombe Blvd., Suite 205, near the Texas Medical Center in Houston. It is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell redirecting cancer immunotherapies.
On July 2, Immatics completed a business combination with Arya Sciences Acquisition…
